Posts Tagged: California Institute for Regenerative Medicine
Berkeley City College, which received a portion of $51 million in state stem cell research grants. (Photo: berkeleyside.org)
The California stem cell agency yesterday awarded $51 million to help train students in the art of research at the Golden State’s community colleges and universities. All 15 applicants for awards that ran as high as $3.6 million each were approved, including Berkeley City College, which was initially rejected by anonymous reviewers who met privately prior to the ratification of their decisions by the agency’s directors.
Mesenchymal stem cells are injected into the knee of a patient. (Photo: Wikimedia Commons photo, via VT Digger)
They could be called the “UC Caucus,” although that may presume too much. Nonetheless, they come from an institution that has pulled down $1.2 billion from the California state stem cell agency, more than any other enterprise during the last 16 years.
Evangelina Padilla-Vaccaro’s medical team gathers around her on the day she received her gene-therapy stem-cell transplant. (Photo: Padilla-Vaccaro family, via UCLA Health)
A London-based biotech firm has given up its life-saving treatment for the bubble baby disease and turned it over to California’s $12 billion stem cell agency and UCLA, where it was developed with tens of millions of taxpayer dollars.
Monica Nava and her 1-year-old daughter Clementine, who suffers from the "bubble baby" affliction. (Family photo).
The story about Jakob, Sheersha and Clementine is a 6,000-mile biomedical tale that spans the Atlantic. The story ranges from the Saskatchewan River in Canada to the dusty Tehachapi mountains in drought-plagued Southern California. And it is a story of children with a terrible and rare genetic affliction known as the bubble baby disease.
A scientist at work in a biomedical laboratory. (Photo: Tom Robertson, via Shutterstock)
The California stem cell agency says it is doing “everything” it can to move forward on a gene therapy that has saved the lives of more than 50 persons but which has been pushed aside by the company that has exclusive rights to it. The issue has raised questions about the ethics of withholding care from babies and children suffering from a fatal disease.
Evangelina, a former 'bubble baby,' plays inside a giant plastic bubble. (Photo: Stem Cellar Report, CIRM)
Little Evangelina Padilla-Vaccaro is more than a poster girl for the $12 billion California stem cell agency. She embodies a big bet by the agency that its efforts will conquer at least a few of the terrible diseases that are currently incurable. In the case of Evie, as the eight-year-old is known, she was born with what has come to be described as the bubble baby syndrome, a rare genetic mutation that crippled her immune system to the point that she would have died if left untreated.
A pipette and receptacles used in stem cell research. (Photo: CI Photos)
The talk at the California stem cell agency this week was of ”boiling the ocean,” the meaning of “unlikely” and “DEI.” All of which involves how $5.5 billion in taxpayer dollars will be used over the next decade or so.
A stem cell researcher at UC Davis. (Photo: AJ Cheline, UC Davis, via The Stem Cellar)
Backed by $17 million in cash from California’s stem cell agency, researchers at UC Davis this month are launching “the world’s first clinical trial using stem cells to treat spina bifida before the child is born.”
Stem cell researcher and professor Larry Goldstein. (Photo: Screen capture, UCTV).
Larry Goldstein, a well-known stem cell researcher at the University of California, San Diego who has received nearly $22 million in awards from the California stem cell agency, today was named to its governing board. It was the first time in the history of the 16-year-old agency that a scientist who has received agency awards has been appointed to the board.
Stem cell research using what's known as a PCR strip. (Image: Science Photo via Shutterstock)
California’s ambitious stem cell agency has launched itself on a new, $5.5 billion journey, approving a plan to hand out $182 million to researchers by the middle of next year and beefing up its efforts to bring equality to therapies and scientific labs.